Comparison of Enzyme Immunoassay and Immunohistochemical Measurements of Estrogen and Progesterone Receptors in Breast Cancer Patients

Ferrero-Poüs, Magali; Trassard, Martine; Doussal, V. Le; Hacène, K.; Tubiana-Hulin, M.; Spyratos, Frédérique

doi:10.1097/00129039-200109000-00012

Cited by 22 publications

(18 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been a shift in clinical practice from using radioligand binding to using IHC for routine ER content analysis of breast cancers (15). Several studies included comparisons of in vitro radioligand-binding assays for ER expression with IHC assays for ER expression (7,16,33,35). These studies showed that the agreement between the 2 methods ranged from 86% to 98%.…”

Section: Discussionmentioning

confidence: 99%

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol

Peterson¹,

Mankoff²,

Lawton³

et al. 2008

J Nucl Med

229

261

View full text Add to dashboard Cite

The PET compound 18 F-fluoroestradiol ( 18 F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18 F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared 18 F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic 18 F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of 18 F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-31), the Allred score (0-10), and a computerized IHC index. Results: There was excellent agreement (r 5 0.99) between observers using IHC as well as the different methods of measuring ER content (P , 0.001). ER-negative tumors had 18 F-FES partial-volumecorrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of 18 F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and 18 F-FES partial-volume-corrected standardized uptake values. Conclusion: Our results showed good agreement between 18 F-FES PET and ER expression measured by IHC. 18 F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol

Peterson¹,

Mankoff²,

Lawton³

et al. 2008

J Nucl Med

229

261

View full text Add to dashboard Cite

show abstract

“…The slides were scanned and all cells were counted in a high-power field (40X). The cases were interpreted as p63, p53, estrogen or progesterone receptor positive if more than 10% of the neoplastic cells showed nuclear staining (16,17). The cases were interpreted as EBNA-1 positive if more than 1% of the neoplastic cells were stained.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?

Ribeiro‐Silva

Ramalho

Garcia

et al. 2004

Braz J Med Biol Res

View full text Add to dashboard Cite

Several investigators have identified Epstein-Barr virus (EBV) particles in breast carcinomas, a fact that supports a role for EBV in mammary tumorigenesis. The possible mechanism involved in this process is not clear. The present study was carried out in an attempt to determine whether there is a relationship between latent infection with EBV and p53 and p63 expression in breast carcinomas. Immunohistochemistry developed with 3.3-diaminobenzidine tetrahydrochloride was performed in 85 formalin-fixed paraffin-embedded breast carcinomas using anti-EBV EBNA-1, anti-p63, anti-p53, anti-estrogen receptor (ER) and anti-progesterone receptor (PR) antibodies. The cases were selected to represent each of the various histologic types: intraductal carcinoma (N = 12), grade I invasive ductal carcinoma (N = 15), grade II invasive ductal carcinoma (N = 15), grade III invasive ductal carcinoma (N = 15), tubular carcinoma (N = 8), lobular carcinoma (N = 10), and medullary carcinoma (N = 10). The ductal breast carcinomas were graded I, II and III based on the Scarff-Bloom and Richardson grading system modified by Elston and Ellis. One slide containing at least 1000 neoplastic cells was examined in each case. ER, PR, p63, p53 and EBNA-1 were positive in 60, 40, 11.8, 21.2 and 37.6% of carcinomas, respectively. There was a correlation between EBNA-1 and p63 expression (P < 0.001), but not between EBNA-1 and p53 (P = 0.10). These data suggest a possible role for p63 in the mammary tumorigenesis associated with Epstein-Barr virus infection.

show abstract

“…Most workers are now agreed that immunocytochemistry for ER is the method of choice [1,4,5,17], and a number of scoring systems have been developed in an attempt to semi-quantify the test. The most complex of these is the H-score, which is still used by a number of laboratories [7].…”

Section: Introductionmentioning

confidence: 99%

Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study

Wells

Sloane²,

Coleman³

et al. 2004

Virchows Arch

View full text Add to dashboard Cite

To assess the variability of oestrogen receptor (ER) testing using immunocytochemistry, centrally stained and unstained slides from breast cancers were circulated to the members of the European Working Group for Breast Screening Pathology, who were asked to report on both slides. The results showed that there was almost complete concordance among readers (kappa=0.95) in ER-negative tumours on the stained slide and excellent concordance among readers (kappa=0.82) on the slides stained in each individual laboratory. Tumours showing strong positivity were reasonably well assessed (kappa=0.57 and 0.4, respectively), but there was less concordance in tumours with moderate and low levels of ER, especially when these were heterogeneous in their staining. Because of the variation, the Working Group recommends that laboratories performing these stains should take part in a external quality assurance scheme for immunocytochemistry, should include a tumour with low ER levels as a weak positive control and should audit the percentage positive tumours in their laboratory against the accepted norms annually. The Quick score method of receptor assessment may also have too many categories for good concordance, and grouping of these into fewer categories may remove some of the variation among laboratories.

show abstract

Comparison of Enzyme Immunoassay and Immunohistochemical Measurements of Estrogen and Progesterone Receptors in Breast Cancer Patients

Cited by 22 publications

References 35 publications

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol

Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?

Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study

Contact Info

Product

Resources

About

Comparison of Enzyme Immunoassay and Immunohistochemical Measurements of Estrogen and Progesterone Receptors in Breast Cancer Patients

Cited by 22 publications

References 35 publications

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol

Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?

Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study

Contact Info

Product

Resources

About

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸F-Fluoroestradiol